NIH SBIR Phase II (Omnibus)
Funds United States small businesses advancing validated biomedical innovations through substantial full development execution.
The NIH SBIR Phase II Omnibus is the National Institutes of Health's primary non-dilutive R&D execution grant for U.S. small businesses that have completed or can demonstrate Phase I-equivalent feasibility work. Issued under activity code R44, Phase II awards are capped at $2,045,816 in total costs and cover one to three years of full research and development — typically prototype construction, an…
Continuation of a successful Phase I project from the same NIH institute or center. Application must demonstrate Phase I milestone completion and a credible path to commercialization.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up